2 not yet recruiting, 1 enrolling by invitation, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Yeon Hee Park: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World) Medical record use research - TNBC - Triple-Negative Breast Cancer | Not yet recruiting | Yeon Hee Park | 2000 | 2026-09-14 | 2026-09-18 | |
| Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer Ribociclib with fulvestrant, Physician's choice treatments group - Breast Cancer Metastatic | Phase 2 | Not yet recruiting | Yeon Hee Park | 272 | 2026-02-01 | 2025-12-24 |
| NEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd Patients With HER2-positive Advanced Breast Cancer Treated With T-DXd, Patients With HER2-low Advanced Breast Cancer Treated With T-DXd | Enrolling by invitation | Yeon Hee Park | 100 | 2025-08-12 | 2026-01-08 | |
| Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer Sacituzumab Govitecan with pegfilgrastim - Breast Cancer Metastatic | Phase 2 | Recruiting | Yeon Hee Park | 40 | 2025-07-03 | 2025-08-28 |
Triple Negative Breast Neoplasms (1)
Fulvestrant (1) · pegfilgrastim (1) · ribociclib (1) · sacituzumab govitecan (1)
South Korea (2)